Andreas Schrodt

Title: Andreas Schrodt: Innovator in Pharmaceutical Chemistry

Introduction

Andreas Schrodt is a notable inventor based in Burgthann, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of crystalline solvated forms of complex compounds. His work is essential for advancing drug formulations and therapeutic applications.

Latest Patents

Andreas Schrodt holds a patent for "Crystalline solvated forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea." This patent relates to the crystalline solvated forms of this compound, methods of making these forms, and their pharmaceutical compositions and kits. The invention also includes methods of treatment and uses involving the administration of these forms.

Career Highlights

Andreas Schrodt is currently associated with Sumitomo Pharma Co., Ltd., where he continues to innovate in the pharmaceutical sector. His expertise in developing new drug formulations has positioned him as a valuable asset in his field. He has successfully contributed to the advancement of pharmaceutical sciences through his research and inventions.

Collaborations

Andreas has collaborated with notable colleagues, including Carsten Jagusch and Christian Klaus Herz. These collaborations have further enhanced the impact of his work in the pharmaceutical industry.

Conclusion

Andreas Schrodt's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his importance in the field. His work continues to influence drug development and therapeutic applications, showcasing the vital role of inventors in advancing healthcare solutions.